Vimarsana
Biggest News Aggregation in the World

Page 9 - Specific Populations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Populations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Populations Today - Breaking & Trending Today

The Menarini Group and its subsidiary Stemline Therapeutics: Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU (Elacestrant) in Metastatic Breast Cancer at ASCO 2023 - Vimarsana News

The Menarini Group and its subsidiary Stemline Therapeutics: Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU (Elacestrant) in Metastatic Breast Cancer at ASCO 2023

ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with

THE MENARINI GROUP AND ITS SUBSIDIARY STEMLINE THERAPEUTICS: Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting - Vimarsana News

THE MENARINI GROUP AND ITS SUBSIDIARY STEMLINE THERAPEUTICS: Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting

The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group, announced today that

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer - Vimarsana News

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer

Results from Phase 3 KEYNOTE-966 to be presented at AACR 2023 Annual Meeting during Clinical Trials Plenary Session, included in official meeting press program and published simultaneously in The... | April 16, 2023

Helsinn Healthcare S.A.: Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV - Vimarsana News

Helsinn Healthcare S.A.: Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV

Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist Lugano, Switzerland, January 4, 2023 - Helsinn Group ("Helsinn")

Helsinn Healthcare S.A.: Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia - Vimarsana News

Helsinn Healthcare S.A.: Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 - Helsinn Group ("Helsinn"), a fully integrated global